The earnings call reflected strong revenue growth and successful strategic execution, particularly in high potential accounts and surgeon training. Challenges remain with gross margin pressures and potential logistical changes due to the BLA approval process. However, the overall financial performance and raised guidance indicate a positive trajectory.

Company Guidance

During the second quarter 2025 earnings call, Axogen provided updated guidance for the fiscal year. The company reported a significant Q2 sales increase of 18.3% to $56.7 million compared to the same period last year, driven by double-digit growth across all target markets, including extremities, oral maxillofacial, and breast. Gross profit rose to $42 million, with a gross margin of 74.2%. Operating expenses reached $40.3 million, highlighting enhanced operating leverage. Axogen achieved a net income of $0.6 million, or $0.01 per share, with adjusted net income at $5.7 million, or $0.12 per share. The company raised its full-year revenue growth guidance to at least 17%, projecting a minimum of $219 million in revenue, and maintained its gross margin guidance between 73% and 75%. Axogen anticipates BLA approval for Avance Nerve Graft in September, securing 12 years of market exclusivity, and expects to remain net cash flow positive, self-funding its strategic plan through growing operational cash flow.

Strong Revenue Growth

Q2 sales increased to $56.7 million, growing 18.3% year-over-year. This reflects double-digit growth across all nerve repair target markets, including extremities, oral maxillofacial and head and neck, and breast.

High Potential Accounts Performance

Approximately 70% of revenue growth driven by high potential accounts. Average high potential account productivity is up 21% year-over-year.

Surgeon Training Success

Met or on track to meet 2025 training targets across all segments, including breast, extremities, and oral maxillofacial and head and neck.

Commercial Coverage Expansion

17 million additional lives covered year-to-date, bringing coverage amongst commercial payers to more than 55%.

Financial Performance and Outlook

Net income for the quarter was $0.6 million, compared to a net loss of $1.9 million in the second quarter of 2024. Adjusted EBITDA for the quarter was $9.3 million. Revenue guidance for 2025 raised to at least 17% growth.

AxoGen (AXGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AXGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.07 / -	0.07	―	―	―
Aug 05, 2025	2025 (Q2)	0.06 / 0.12	0.05	140.00% (+0.07)
May 08, 2025	2025 (Q1)	0.01 / -0.02	-0.06	66.67% (+0.04)	―
Feb 25, 2025	2024 (Q4)	0.04 / 0.07	-0.06	216.67% (+0.13)
Nov 07, 2024	2024 (Q3)	<0.01 / 0.07	0.01	600.00% (+0.06)
Aug 08, 2024	2024 (Q2)	-0.06 / 0.05	-0.03	266.67% (+0.08)
May 02, 2024	2024 (Q1)	-0.07 / -0.06	-0.1	40.00% (+0.04)	―
Mar 05, 2024	2023 (Q4)	-0.07 / -0.06	-0.03	-100.00% (-0.03)	―
Nov 07, 2023	2023 (Q3)	-0.06 / 0.01	-0.01	200.00% (+0.02)
Aug 07, 2023	2023 (Q2)	-0.12 / -0.03	-0.06	50.00% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AXGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$12.55	$13.72	+9.32%
May 08, 2025	$16.39	$12.59	-23.18%
Feb 25, 2025	$18.01	$20.11	+11.66%
Nov 07, 2024	$15.33	$13.27	-13.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AxoGen (AXGN) report earnings?

AxoGen (AXGN) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is AxoGen (AXGN) earnings time?

AxoGen (AXGN) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AXGN EPS forecast?

AXGN EPS forecast for the fiscal quarter 2025 (Q3) is 0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing